Overview

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

Status:
Unknown status

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

Prospective, Open Label, Cohort Study in Traumatic Brain Injury Patients. The goal of this study is to assess the safety of NTx®-265. NTx®-265 will be administered over 9 days, and patients will be followed for an additional 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

University of Calgary

Collaborators:

Stem Cell Therapeutics Corp.
Stem Cell Theraputics

Treatments:

Chorionic Gonadotropin
Epoetin Alfa